About US
Contact us
-
Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boostGlaxoSmithKline giantAdvairmay be reeling, but it hasn't kicked the bucket yet. And now, it's getting a payer boost that will breathe a little life into falling sales. With dismal second-quarter resul2014/8/5
-
Sanofi plots FDA app for blockbuster-to-be dengue vaccine in early 2015Sanofi's ($SNY) in line to rack up blockbuster sales after hitting a wide-open market with itsdenguevaccine, analysts predict. And company CEOChris Viehbacherthinks those sales could start rolling in2014/8/4
-
Novo Nordisk more valuable than GlaxoSmithKline? That's what investors sayWho'd have thought Novo Nordisk ($NVO) could zoom past GlaxoSmithKline ($GSK) in the pharma market value rankings? Predictable or not, that's just what's happened. AsBloombergreports, Novo shares are2014/8/1
-
Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall's lung medsAstraZeneca ($AZN) is staring down the barrel at rivals for its blockbuster respiratory drugSymbicort, branded and generic. CEO Pascal Soriot has respiratory drugs on his list of growth drivers. He's2014/7/31
-
Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebidNo news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEOIan Read's next buyout move was disappointed after Tuesday's second-quarter earnings2014/7/31
-
J&J, Pharmacyclics celebrate yet another nod for leukemia med ImbruvicaJohnson & Johnson's ($JNJ) new blood cancer drugImbruvica(ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulato2014/7/30
-
China sets trial date for GSK-tied investigators, says it will be 'open'It's official: China has set the date for the trial of two private investigators tied to GlaxoSmithKline's operations there. The pair will head to court in just over a week on charges of illegally pur2014/7/30
-
Roche, Novartis protest moves in EU to pay for off-label AvastinLast week,Francemade its move to knock the Novartis eye drugLucentisout of drug coverage and move its cheaper cousinAvastininto its place. Now, Novartis and its Lucentis partner Roche are fighting bac2014/7/29
-
Merck whacks 600 sales reps as part of 8,500 bloodlettingMerck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sal2014/7/28
-
FDA approves Gilead Sciences’ Zydelig for three types of blood cancersGilead Sciences has obtained US Food and Drug Administration (FDA) approval for its Zydelig (idelalisib) 150mg tablets for treatment of three B-cell blood cancers. Zydelig is an oral inhibitor of pho2014/7/28